
https://www.science.org/content/blog-post/long-delayed-cox2-issue-gets-settled-450-million
# A Long‑Delayed COX‑2 Issue Gets Settled – For $450 Million? (May 2012)

## 1. SUMMARY  
The 2012 commentary recounted the tangled patent history surrounding cyclooxygenase‑2 (COX‑2) inhibitors. After the enzyme’s discovery in the early 1990s, several institutions claimed priority: Dan Simmons (BYU) and Donald Young (University of Rochester). Rochester’s broad “method‑of‑use” patent was eventually invalidated for lacking a sufficient written description, while Simmons sued Monsanto for breach of contract after the company allegedly discouraged him from filing patents.  

The article noted that Pfizer, the marketer of the COX‑2 drug celecoxib (Celebrex), announced an “amicable settlement” with BYU that was confidential except for a $450 million charge to earnings and the creation of a Dan Simmons Chair at BYU. The author wondered whether this large payment signaled the final resolution of the long‑running COX‑2 discovery wars.

## 2. HISTORY  
**Settlement outcome (2012‑2013)**  
- In May 2012 Pfizer disclosed a $450 million settlement with BYU and Dan Simmons. The agreement ended Simmons’ patent‑infringement claims that Pfizer’s celecoxib infringed on patents covering COX‑2 inhibitor chemistry that Simmons had helped discover while under contract with Monsanto.  
- The public terms were limited to the cash payment and the establishment of the Dan Simmons Chair in the BYU College of Life Sciences. No ongoing royalty stream was announced, suggesting the payment was a lump‑sum resolution.  

**Impact on celecoxib and the COX‑2 market**  
- Celebrex remained on the market; the settlement did **not** affect its FDA status or availability.  
- In 2014 the U.S. FDA approved the first generic version of celecoxib (generic “celecoxib”). This dramatically reduced Pfizer’s revenue from the drug, but the settlement had already been accounted for, so Pfizer’s earnings were not materially altered by the generic launch.  

**Broader COX‑2 landscape**  
- After Merck’s withdrawal of rofecoxib (Vioxx) in 2004, the industry’s enthusiasm for COX‑2‑selective drugs waned. No new COX‑2‑selective small‑molecule drugs have received FDA approval since 2012.  
- Safety warnings (increased cardiovascular risk) were added to celecoxib’s label in 2014, but the drug continues to be prescribed for osteoarthritis, rheumatoid arthritis, and acute pain, albeit at lower market share than in its early 2000s peak.  

**Legal aftermath**  
- The University of Rochester’s earlier patent battle concluded years earlier with the court ruling that its “method‑of‑use” patent was invalid for lack of written description. No further litigation involving Rochester’s COX‑2 patents has surfaced since the Pfizer settlement.  
- BYU’s Dan Simmons Chair was created in 2012 and remains funded; there have been no public disputes indicating the settlement was renegotiated or contested.  

**Business consequences**  
- Pfizer’s $450 million charge was recorded as a one‑time expense in Q2 2012; the company’s long‑term financial trajectory was more heavily influenced by the loss of exclusivity on celecoxib and broader portfolio shifts (e.g., the 2020 acquisition of Seagen).  
- The settlement effectively closed the “COX‑2 discovery wars” from a legal standpoint; no major parties have pursued further COX‑2‑related patent claims since then.

## 3. PREDICTIONS  
| Prediction in the article (or implied) | What actually happened | Assessment |
|---|---|---|
| **“Last shot … quietly … settled for $450 M”** – a large cash settlement would end the dispute. | Pfizer paid $450 M to BYU/Simmons and the case was closed. | Accurate – the settlement occurred as described. |
| **Implication that the settlement would have major market impact** (i.e., affect COX‑2 drug availability). | Celebrex stayed on the market; only later did generic competition reduce sales. | Not realized – the settlement did not change drug availability. |
| **Expectation that COX‑2 patents would finally be resolved** (no further litigation). | No notable COX‑2 patent lawsuits have emerged after 2012. | Accurate. |
| **Suggestion that the $450 M charge signals a “final” financial hit** for Pfizer. | Pfizer recorded the charge in 2012; subsequent earnings were more affected by generic entry and other portfolio changes. | Partially accurate – the charge was a one‑off, but later revenue declines were driven by other factors. |

## 4. INTEREST  
**Rating: 6/10** – The piece is of moderate historical interest: it documents a rare, high‑value settlement that closed a long‑standing academic‑industry patent saga, but the event had limited downstream scientific or therapeutic impact.  

---  

*All statements are based on publicly available information up to January 2026. Where precise details (e.g., confidential settlement clauses) are not disclosed, confidence is moderate to high for the disclosed facts and lower for any inferred terms.*


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20120503-long-delayed-cox2-issue-gets-settled-450-million.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_